Search

everythinglearnresearchcommunity

for

Search:↓

Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.

Genetic discoveries are leading to new treatments for alopecia areata.

Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Eclipta alba extract may help fight cancer and has antioxidant benefits without being toxic.

Adults with Tatton-Brown-Rahman syndrome may have serious heart problems and need lifelong heart monitoring.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.

Biochanin A from soy is a promising and safe candidate for treating hair loss.

Oclacitinib maleate successfully treated alopecia in Andean bears.

AC5 improves hair loss and hair quality with high satisfaction rates.

The document's conclusion cannot be provided because the content is not available.

The excimer lamp is a safe and effective treatment for severe alopecia areata.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Both laser and microneedling are effective for treating resistant alopecia areata.

Early-stage Alopecia Areata was effectively treated in less than six months.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Hair-loss trials have increased, but need more diverse participants and standardized measures.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

The drug combination was safe and showed promise in treating advanced tumors.

VB1953 gel significantly reduced acne and resistant bacteria in patients who didn't respond to clindamycin.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.